Kidneys Home > Omontys Dosage

Omontys is a medication given as an injection under the skin or as an intravenous infusion once a month. Your individual dose of Omontys will be calculated based on how much you weigh, how you respond to the medication, and other factors. It is important that the amount of this medication be increased gradually, in order to give the medication a chance to work.

In February 2013, Omontys was pulled from the market (all of the product was recalled) to investigate reports of dangerous allergic reactions, including fatal anaphylactic reactions, which appear to be occurring more frequently than anticipated. This medication will not be available until further notice.

An Introduction to Dosing With Omontys

The dose of Omontys® (peginesatide) your healthcare provider recommends will vary, depending on a number of factors, including:
  • Your previous dosage of other similar medications
  • How you respond to Omontys (as measured by blood tests)
  • Your weight.
As always, do not adjust your dose unless your healthcare provider specifically tells you to do so.

What Is the Recommended Dosage of Omontys?

If you have not already been taking a different erythropoiesis-stimulating agent (ESA), the recommended starting Omontys dosage is based on your weight -- 0.04 mg per kg of body weight per month (about 0.018 mg per lb per month).
If you are switching to Omontys from another ESA, such as epoetin alfa (Epogen®, Procrit®) or darbepoetin alfa (Aranesp®), your healthcare provider will calculate your starting Omontys dosage based on your most current amount of epoetin alfa or darbepoetin alfa.
Your healthcare provider will check your progress frequently, using a blood test that measures the amount of hemoglobin in your blood. He or she will adjust your dose in order to gradually increase your hemoglobin to a safe level (too high can be just as dangerous as too low). Studies have shown that using ESAs, including Omontys, to increase the hemoglobin above 11 g/dL increases the risk of death, serious heart problems, blood clots, and strokes. Studies have not found a dosage, dosing strategy, or hemoglobin target level that does not increase these risks.
Your dose should not be increased more frequently than once a month, in order to give the medicine a chance to work. If your hemoglobin increases too quickly or too much, your healthcare provider should decrease your dose or stop it temporarily.
Omontys can be given as an injection under the skin (a subcutaneous injection) or as a slow injection into a vein (an intravenous, or IV, infusion) during dialysis.
Written by/reviewed by:
Last reviewed by: Kristi Monson, PharmD;
Last updated/reviewed:
List of references (click here):
Other Articles in This eMedTV Presentation

Topics & Medications


Related Channels

eMedTV Links
Copyright © 2006-2019 Clinaero, Inc.

eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.

This site complies with the HONcode standard for trustworthy health information:
verify here.